SUO 2019 the value of critical assessment of one’s own institution’s outcomes to drive patient outcomes, innovations that have led to current phase I and phase II trials, UTSW SAbR experience.
AUA 2025 ARANOTE trial (NCT04736199), ad hoc analysis of the phase III ARANOTE trial, efficacy and safety of darolutamide + ADT in black patients with…
AUA 2025 State-of-the-Art Lecture on Urothelial Markers, biomarkers for urothelial cancer, Tissue based biomarkers, RETAIN-2 trial, membranous Nectin-4 in urothelial cancer, CxBladder.
AUA 2025, Bladder Cancer, Evolving Role of Surgery for Bladder Cancer, robot-assisted radical cystectomy (RARC) open radical cystectomy (ORC), a standard pelvic lymph node dissection…
AUA 2025 phase 3 ENLIGHTED study, padeliporfin vascular targeted photodynamic (VTP) therapy for treatment of low-grade upper tract urothelial cancer.
AUA 2025 phase 3 OLYMPUS trial, UGN-101, low-grade upper tract urothelial carcinoma, upper tract urothelial carcinoma tumor recurrence, uTRACT registry (NCT05874921).
AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Upfront Cytoreductive Nephrectom, Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma, CARMENA trial,
AUA 2025 performance of minimal residual disease detection with urine-derived DNA, high-grade bladder cancer, recommended repeat TURBT, UroAmp.
AUA 2025, prostate cancer, 18F-DCFPyL, 18F-FDG PET/CT, Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT, dual-tracer (¹⁸F-DCFPyL and ¹⁸F-FDG) PET/CT imaging.
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
AUA 2025, kidney cancer, renal cell carcinoma (RCC), metastatic renal cell carcinoma (mRCC), Nivolumab, Ipilimumab, Nivolumab plus Ipilimumab Therapy, sunitinib, Primary Resistance to Nivolumab plus…
